Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up

European Journal of Cancer

Volumn 44, Issue 16, 2008, Pages 2485-2495

  Schlesinger Raab, Anne ^a   Treiber, Uwe ^b   Zaak, Dirk ^c   Hölzel, Dieter ^a   Engel, Jutta ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cancer registry; Kidney cancer; Metastases; Population based; Renal cell carcinoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 54249130642     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.039     Document Type: Article

References (22)

1. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon, France: IARC Press; 2004 [updated 2004 cited 2004]; IARC CancerBase No. 5. version 2.0. Globocan2002 - tables by cancer.
2. Bertz J, Giersiepen K, Haberland J, et al. Krebs in Deutschland. Häufigkeiten und Trends. 5. überarbeitete und aktualisierte. In: Ausgabe ed. e.V. GdeKiD, Robert-Koch-Institut, editors. Saarbrücken; 2006.
3. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
4. Campbell S.C., Flanigan R.C., and Clark J.I. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 4 (2003) 363-372
5. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 25 (2005) CD001425
6. Aben K.K.H., Luth T.K., Janssen-Heijnen M.L.G., Mulders P.F., Kiemeney L.A., and van Spronsen D.J. No improvement in renal cell carcinoma survival: A population-based study in the Netherlands. Eur J Cancer 44 (2008) 1701-1709
7. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356 (2007) 115-124
9. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388s-6392s
10. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 349 (2003) 427-434
11. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J.W.W. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 (2008) 1345-1389
12. Ries L, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2003. Bethesda, MD: National Cancer Institute; 2006 [updated 2006; cited]. .
13. Luciani L.G., Cestari R., and Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 56 (2000) 58-62
14. Gudbjartsson T., Thoroddsen A., Petursdottir V., Hardarson S., Magnusson J., and Einarsson G.V. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 66 (2005) 1186-1191
15. Kurzgefasste interdisziplinäre Leitlinien 2002. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften; 2002. .
16. Elson P.J., Witte R.S., and Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48 (1988) 7310-7313
17. Seaman E.K., Ross S., and Sawczuk I.S. High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma. J Neurooncol 23 (1995) 253-256
18. Langmark F, Hoff G, Johannesen TB, et al. Cancer in Norway 2004. Oslo, Norway: Cancer Registry of Norway - Institute of Population-based Cancer Research; 2006.
19. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169 (2003) 2076-2083
20. Joslyn S.A., Sirintrapun J., and Konety B.R. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National surveillance, epidemiology, and end results database. Urology 65 (2005) 675-680
21. Motzer R.J., Michaelson M.D., Rosenberg J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178 (2007) 1883-1887
22. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rafamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918